EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival

John I Robinson iD, Laura R Marks, Andrew L Hinton, Jane A O'Halloran, Charles W Goss, Peter J Mucha, Jeffrey P Henderson iD

mBio · 2025

DOI: 10.1128/mbio.03343-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2025. Verfasst von John I Robinson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: COVID-19, Metabolome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: James S. McDonnell Foundation (JSMF), Foundation for Barnes-Jewish Hospital (FBJH), The Longer Life Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a new respiratory virus pandemic, optimizing allocation of scarce medical resources becomes an urgent challenge. Infection prognosis takes on particular importance when allocating scarce antiviral antibodies and drugs, which are most effective when administered before the onset of severe disease. During arrival of the COVID-19 pandemic to the United States in 2020, we conducted a prognostic biomarker discovery and validation effort based upon metabolomic profiling with a liquid-chromatography-mass spectrometer (LC-MS) type used clinically for rapid toxicology. We obtained urine specimens from 163 patients presenting for evaluation. We obtained LC-MS profiles in the initial cohort and used machine learning methods to define a simplified urine metabolomic signature associated with respiratory failure or death by 90 days. This signature was composed of three metabotypes linked to intestinal microbiome metabolism and anticonvulsant use, with a receiver-operator characteristic area under the curve (ROC AUC) of 89.4%. Blinded application of this signature to the subsequent validation cohort yielded a ROC AUC of 81.2%. A model trained on the two baseline metabotypes present before intubation exhibited similar performance in the validation cohort. This study demonstrates the plausibility and promise of rapid metabolome-based prognostic discovery and validation in the opening wave of a pandemic. The approach used here could be used to inform therapeutic and resource allocation decisions early in a future epidemic. IMPORTANCE In a new respiratory virus pandemic, the ability to identify patients at greatest risk for severe disease is essential to direct scarce medical resources to those most likely to benefit from them. Tools to predict disease severity are best developed early in a pandemic, but laboratory-based resources to develop these may be limited by available technology and by infection precautions. Here, we show that an accessible metabolic profiling approach could identify a prognostic signature of severe disease in the initial wave of COVID-19, when patients presenting for care often exceeded the available doses of convalescent plasma and remdesivir. In a future pandemic, this approach, alongside efforts to identify clinical disease severity predictors, could improve patient outcomes and facilitate therapeutic trials by identifying individuals at high risk for severe disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19MetabolomeHumansPrognosisMaleFemaleMiddle AgedBiomarkersAgedMetabolomicsChromatography, LiquidSARS-CoV-2Mass SpectrometryAdultCohort Studies

Stichwörter der Autor:innen

COVID-19metabolomicsprognostic indicators

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Curriculum in Bioinformatics and Computational Biology, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Mathematics, Dartmouth College, Hanover, New Hampshire, USA.

ORCID-Profile: John I Robinson, Jeffrey P Henderson

Förderung

  • James S. McDonnell Foundation (JSMF)
  • Foundation for Barnes-Jewish Hospital (FBJH)
  • The Longer Life Foundation
  • HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
  • NCATS NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)
  • NIDDK NIH HHS
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Zitieren

APA

Robinson, J. I., Marks, L. R., Hinton, A. L., O'Halloran, J. A., Goss, C. W., Mucha, P. J., & Henderson, J. P. (2025). Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival. mBio. https://doi.org/10.1128/mbio.03343-23

Vancouver

Robinson JI, Marks LR, Hinton AL, O'Halloran JA, Goss CW, Mucha PJ, et al. Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival. mBio. 2025. doi:10.1128/mbio.03343-23

BibTeX
@article{Robinson2025,
  author = {Robinson, John I and Marks, Laura R and Hinton, Andrew L and O'Halloran, Jane A and Goss, Charles W and Mucha, Peter J and Henderson, Jeffrey P},
  title = {Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival},
  journal = {mBio},
  year = {2025},
  doi = {10.1128/mbio.03343-23}
}
Kostenlos starten →